Alterity Therapeutics (ASX:ATH, NASDAQ: ATHE), a clinical stage biotechnology company focused on neurodegenerative disease treatments, has disclosed that Chief Executive Officer David Stamler, M.D., will present at the virtual Bell Potter Healthcare Conference on Thursday, 19 November 2026 at 12:00 p.m. AEDT.
Key Points
- CEO David Stamler, M.D., will present at the virtual Bell Potter Healthcare Conference on 19 November 2026 at 12:00 p.m. AEDT.
- An archived webcast will be made available after the event via the Investors section of the company's website under Events and Presentations.
- Alterity is preparing to initiate a Phase 3 pivotal trial in Multiple System Atrophy (MSA), a rare and rapidly progressive neurodegenerative disease without an approved treatment.
- The company's lead asset, ATH434, demonstrated clinically meaningful efficacy in a randomised, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA.
Bell Potter Healthcare Conference Presentation Details
Alterity Therapeutics disclosed that Chief Executive Officer David Stamler, M.D., is scheduled to present at the virtual Bell Potter Healthcare Conference on Thursday, 19 November 2026, commencing at 12:00 p.m. AEDT. The company stated that an archived webcast link will be made available following the event and can be accessed through the Investors section of the Alterity Therapeutics website under Events and Presentations. The filing was authorised by David Stamler in his capacity as CEO of Alterity Therapeutics Limited. The company is dual-listed on the ASX and NASDAQ under the ticker symbols ATH and ATHE respectively.
ATH434 Clinical Programme in Multiple System Atrophy
According to the filing, Alterity is preparing to initiate a Phase 3 pivotal trial in Multiple System Atrophy, described as a rare and rapidly progressive neurodegenerative disease for which no approved treatment currently exists. The company's lead asset, ATH434, is stated to have demonstrated clinically meaningful efficacy in a randomised, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has also reported positive data from an open label Phase 2 clinical trial in participants with advanced MSA, according to the company disclosure.
Company Focus and Drug Discovery Platform
The filing describes Alterity Therapeutics as a clinical stage biotechnology company dedicated to developing disease modifying therapies for Parkinson's disease and related disorders, with a specific focus on neurodegenerative diseases. In addition to its clinical programmes, the company disclosed it maintains a broad drug discovery platform generating patentable chemical compounds directed at treating the underlying pathology of neurological diseases. Alterity is based in Melbourne, Australia, and San Francisco, California, USA, according to the filing.





_11_18_2026_12_41_48_650646.jpg)
Please wait processing your request...